Health care utilisation and costs in the general population in Germany

Grupp, Helen; König, Hans‐Helmut; Konnopka, Alexander

doi:10.1016/j.healthpol.2015.11.005

Cited by 20 publications

(25 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of publications reporting unit costs or cost sources, fewer were identified for France (n = 9) [30-37] than for Germany (n = 15) [23,[38][39][40][41][42][43][44][45][46][47][48][49][50] or Italy (n = 15) [51][52][53][54][55][56][57][58][59][60][61][62][63][64], with one study reporting data for all three countries [65]. A range of cost sources and unit costs could be obtained from these studies for the resource use items of interest (Table 1).…”

Section: Results For Unit Costs and Cost Data Sourcesmentioning

confidence: 99%

Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy

Pöhlmann¹,

Norrbacka²,

Boye

et al. 2020

Eur J Health Econ

View full text Add to dashboard Cite

Background Health economic evaluations require cost data as key inputs. Many countries do not have standardized reference costs so costs used often vary between studies, thereby reducing transparency and transferability. The present review provided a comprehensive overview of cost sources and suggested unit costs for France, Germany and Italy, to support health economic evaluations in these countries, particularly in the field of diabetes. Methods A literature review was conducted across multiple databases to identify published unit costs and cost data sources for resource items commonly used in health economic evaluations of antidiabetic therapies. The quality of unit cost reporting was assessed with regard to comprehensiveness of cost reporting and referencing as well as accessibility of cost sources from published cost-effectiveness analyses (CEA) of antidiabetic medications. Results An overview of cost sources, including tariff and fee schedules as well as published estimates, was developed for France, Germany and Italy, covering primary and specialist outpatient care, emergency care, hospital treatment, pharmacy costs and lost productivity. Based on these sources, unit cost datasets were suggested for each country. The assessment of unit cost reporting showed that only 60% and 40% of CEAs reported unit costs and referenced them for all pharmacy items, respectively. Less than 20% of CEAs obtained all pharmacy costs from publicly available sources. Conclusions This review provides a comprehensive account of available costs and cost sources in France, Germany and Italy to support health economists and increase transparency in health economic evaluations in diabetes.

show abstract

Section: Results For Unit Costs and Cost Data Sourcesmentioning

confidence: 99%

Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy

Pöhlmann¹,

Norrbacka²,

Boye

et al. 2020

Eur J Health Econ

View full text Add to dashboard Cite

show abstract

“…The dataset used for comparison came from a telephone survey [19]. The sample is representative of the total German-speaking population aged 18 years and older.…”

Section: Methodsmentioning

confidence: 99%

“…In total, 5005 individuals completed the telephone interview. A description of the dataset can be found elsewhere [19]. As individuals in this dataset should serve as an anxiety free control group in our analysis, we excluded individuals with anxiety disorders (n = 265) or with a score of at least 3 on the PHQ-4 anxiety module [21] (n = 1448).…”

Section: Methodsmentioning

confidence: 99%

The allocation of resources in the care for patients with panic disorder in Germany: an excess cost analysis informing policy and science

Brettschneider

Bleibler

Hiller

et al. 2019

Cost Eff Resour Alloc

Self Cite

View full text Add to dashboard Cite

Background Panic disorder is a mental disorder of high prevalence, which frequently co-occurs with agoraphobia. There is a lack of studies measuring excess costs of panic disorder patients with and without agoraphobia. We compared costs of panic disorder patients with or without agoraphobia with costs of the anxiety-free population in Germany. Methods Primary data from a cluster-randomized trial of adults suffering from panic disorder (n = 419) and from a representative survey of the German general population (N = 5005) were collected between 2012 and 2014. Missing data from the cluster-randomized trial were first imputed by multiple imputation using chained equations and subsequently balanced with the data from the survey by Entropy Balancing. The societal perspective was chosen. Excess costs were calculated by generalized linear models and two-part-models. Results Entropy Balancing led to an exact match between the groups. We found 6-month total excess costs of 3220€ (95% CI 1917€–4522€) for panic disorder patients without agoraphobia and of 3943€ (95% CI 2950€–4936€) for patient with agoraphobia. Panic disorder patients with or without agoraphobia had significantly higher costs for psychotherapy, general practitioners, general hospital stays and informal care Indirect costs accounted for approximately 60% of the total excess costs. Conclusions Panic disorder with or without agoraphobia is associated with significant excess costs. Agoraphobia changes the pattern of resource utilization. Especially indirect costs are relevant. Agoraphobia influences resource utilization in the inpatient sector. Trial registration ISRCTN64669297

show abstract

“…Adipositas und Normalgewicht auf die gesamte deutsche Erwachsenenbevölkerung extrapoliert. Als Grundlage für diese Extrapolation haben wir alters-und geschlechtsspezifische Normwerte von direkten und indirekten Kosten (K Bevölkerung ) verwendet, die wir auf Basis einer bevölkerungsrepräsentativen Befragung berechnet hatten [7]. Aus derselben Befragung haben wir auch die für die Extrapolation nötigen Prävalenzen (P) von Normalgewicht (N), Übergewicht (Ü) und Adipositas (A) entnommen.…”

Section: Datenextraktion Und Datenaufbereitungunclassified

Die Kosten von Übergewicht und Adipositas in Deutschland – ein systematischer Literaturüberblick

et al. 2017

Self Cite

View full text Add to dashboard Cite

We found substantial heterogeneity of cost findings between studies for top-down and bottom-up studies as well, which points to substantial uncertainty and strongly hampers clear statements about the costs of overweight and adiposity. Our findings imply that costs are underestimated by top-down studies, whereas overestimated by our extrapolation. The true costs presumably lie between the findings of both approaches.

show abstract

Health care utilisation and costs in the general population in Germany

Cited by 20 publications

References 8 publications

Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy

Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy

The allocation of resources in the care for patients with panic disorder in Germany: an excess cost analysis informing policy and science

Die Kosten von Übergewicht und Adipositas in Deutschland – ein systematischer Literaturüberblick

Contact Info

Product

Resources

About